Psoriasis
Conditions
Interventions
Sponsors
Department of Dermatology, Tongji Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: (1) Age 18 years old (2) psoriasis patients diagnosed by experienced dermatologists who can improve various examinations and epidemiological investigations.(3) After the dermatologist evaluated the patient's condition and reviewed the results of each examination, it was clear that the patient is suitable for using IL-12 / 23 inhibitor biological agents for psoriasis treatment.(4) The function level of the internal organs of the patient should meet the following requirements: a) Blood: Absolute neutrophil count (ANC) 2.0 * 10^9 / L, Platelet, 100 * 10^9 / L, Hemoglobin 9 g/dl; b) Liver: 1.5 times the normal upper limit of bilirubin, Aspartate aminotransferase (AST) and alanine transaminotransferase (ALT) 2.5 times upper normal limit; c) kidney: 1.25 times upper limit of serum creatinine or creatinine clearance 60 mL/min; (5) women of childbearing age must have a blood pregnancy test within 1 week before enrollment with negative results; (6) understand and voluntarily sign a written informed consent.
Exclusion criteria
Exclusion criteria: (1) Age is <18 years old.(2) during pregnancy or lactation; (3) unable / refused to regulate the treatment of umab; (4) received systemic therapy or phototherapy within 4 weeks, Or receive topical treatment within 2 weeks; (5) patients who may need additional local therapy, phototherapy, or other systematic methods for disease treatment during the observation period; (6) the patients have the following unsuitable for treatment of the biological agents: a) patients with a history of malignant tumor or concurrent malignancy in the previous 5 years; b) patients who have received live attenuated vaccination within 4 weeks prior to the proposed first administration of the biological agents, Or patients who are scheduled to receive live attenuated vaccination during observation; c) any history of infection or recurrent infection requiring systemic antibiotic therapy within 2 weeks before the first dose of the organism; d) positive test result against human immunodeficiency disease (HIV) antibody (HIV Ab), And / or positive treponemundum-specific antibodies; And / or positive for hepatitis C virus antibody (HCV Ab), And tested positive by HCV-RNA reverse transcript polymerase chain reaction, Previous or current infection; And / or hepatitis B surface antigen (HbsAg) positive, Or positive hepatitis B core antibody (HBcAb) and positive by HBVDNA polymerase chain reaction, Suggesting the presence of current infection; e) severe, progressive, or uncontrolled renal, liver, blood, gastrointestinal, endocrine, pulmonary, and nervous system diseases; f) patients allergic to any excipients in the biologic or preparation; g) other conditions unsuitable for biologic after evaluation by the specialist.(7) having any other contraindications to relevant organisms or may put the subject at high risk of biological treatment related complications; (8) the investigator believes the subject is not able to complete the study or to comply with the requirements of the study (for management reasons or otherwise).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The portion of MAIT in lymphocytes; | — |
Secondary
| Measure | Time frame |
|---|---|
| inflammatory factor ;Expression of transcription factors in IL-17-associated MAIT cells;Expression of surface activation and depletion markers;Expression of the cell-surface chemokine receptors; | — |
Countries
China
Contacts
Public ContactDeng Yunhua
Department of Dermatology, Tongji Hospital
Outcome results
None listed